TICKERNERD
Menu
MYGNMYGNHealthcare · Diagnostics & Research

MYGN Stock Forecast: Myriad Genetics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$3.04
−5.00% on the day

The 9 Wall Street analysts covering Myriad Genetics, Inc. hold a median 12-month price target of $3.6 — +18.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$306.1M
Ticker Nerd rank
52 / 100
Median analyst target
$3.60
Analysts covering
9
Revenue$190.7M−10.5% y/y
Operating income−$38.9M
Net income−$43.2M
Free cash flow−$11.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.3%
1M
−45.8%
YTD
−50.6%
1Y
−49.5%
From 52W high
−62.8%
From 52W low
+6.3%
$2.86
$8.18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MYGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Myriad Genetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
52 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
96
Value
72
Quality
66
Size
62
Growth
57
Volatility
51
Momentum
37
Revisions
26
Issuance
18

Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MYGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MYGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00$7.00$8.00Oct 25Jan 26Apr 26Jul 26MYGNHigh $5.45Median $3.60Low $2.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
2 Buy5 Hold2 Sell
Low $2.50Median $3.60High $5.45

The green dot is the last close — the median target sits +18.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
18 Aug 2026Stephens & Co.MaintainsEqual-Weight$5.00 → $3.00
3 Aug 2026Wells FargoMaintainsEqual-Weight—
3 Aug 2026Wells FargoMaintainsEqual-Weight$5.50 → $3.00
31 July 2026TD CowenMaintainsHold—
31 July 2026TD CowenMaintainsHold$6.00 → $4.00
6 May 2026TD CowenMaintainsHold$7.00 → $6.00
6 May 2026TD CowenMaintainsHold—
6 May 2026Wells FargoMaintainsEqual-Weight—
6 May 2026Wells FargoMaintainsEqual-Weight$6.00 → $5.50
24 Feb 2026UBSMaintainsNeutral—
24 Feb 2026Wells FargoMaintainsEqual-Weight—
11 Nov 2025Piper SandlerMaintainsOverweight—
5 Nov 2025Wells FargoMaintainsEqual-Weight—
4 Nov 2025TD CowenMaintainsHold—
4 Nov 2025UBSMaintainsNeutral—
21 May 2025ScotiabankDowngradeSector Perform—
15 May 2025Piper SandlerMaintainsOverweight—
8 May 2025Wells FargoDowngradeEqual-Weight—
7 May 2025Goldman SachsMaintainsBuy—
7 May 2025Raymond JamesReiteratesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MYGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MYGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Myriad Genetics, Inc. returned −49.5% against +19.6% for the S&P 500, dividends included.

MYGN vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Oct 25Jan 26Apr 26Jul 26MYGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MYGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1624.4%
Analysts raising
0
Analysts cutting
6
Fundamentals

Myriad Genetics, Inc. (MYGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.8×

Cheaper than 82% of US stocks

Price / sales
0.5×

Cheaper than 81% of US stocks

Price / book
1.0×

Cheaper than 74% of US stocks

EV / EBITDA
−1.4×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
−20.8%

Higher than 11% of US stocks

Earnings growth (YoY)
−10.5%

Higher than 25% of US stocks

Gross margin
66.6%

Higher than 80% of US stocks

Operating margin
−21.4%

Higher than 21% of US stocks

Net margin
−41.3%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−23.5%

Higher than 30% of US stocks

Return on assets
−7.6%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Myriad Genetics, Inc. (MYGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Myriad Genetics, Inc. has a market value of $306.1M and an enterprise value of $155.4M.

  • Revenue in the twelve months to 30 June 2026: $806.6M. The latest quarter shrank 20.8% year on year.

  • Net income over the same four quarters: −$112.6M, a −14.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.19.

  • Free cash flow in the twelve months to 30 June 2026: −$14.2M, after $21.9M of capital spending.

  • Shares outstanding: 94.4M.

  • Trailing P/E: −0.8×; forward P/E: −5.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Myriad Genetics, Inc. employs 2,700 people — $299K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 23 Aug 2026

Data provided by Twelve Data

Peers

MYGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
MYGNMyriad Genetics, Inc.$306.1M
52
BDSXBiodesix, Inc.$275.8M
87
XGNExagen, Inc.$190.5M
66
FLGTFulgent Genetics, Inc.$565.2M
46
IMDXInsight Molecular Diagnostics, Inc.$139.6M
39
QUCYQuantum Cyber NV$109.3M
6
CSTLCastle Biosciences, Inc.$998.3M
87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Myriad Genetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MYGN news & analysis

MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

Business Wire · 14 Aug 2026negative

A law firm, Kirby McInerney LLP, has announced an investigation into Myriad Genetics and its senior management regarding potential violations of federal securities laws. The investigation follows the company's July 30, 2026 report of an 11% year-over-year decline in second-quarter revenue.

Why it matters — This securities-law investigation adds legal risk and uncertainty for Myriad Genetics shareholders, particularly following the company's recent revenue decline.

Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky

PRNewsWire · 10 Aug 2026negative

Myriad Genetics reported Q2 2026 revenue of roughly $190.7 million, below the consensus estimate of $206-208 million, and cut its full-year revenue guidance by about $90 million while suspending adjusted EBITDA guidance. Levi & Korsinsky has launched an investigation into potential securities law violations on behalf of MYGN investors.

Why it matters — A revenue miss, a significant guidance cut, and a securities investigation could signal serious operational or disclosure issues for Myriad Genetics.

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

Business Wire · 8 Aug 2026negative

SBS Law announced that Myriad Genetics investors may have an opportunity to join a fraud investigation into the company. The notice is directed at MYGN shareholders and relates to potential securities concerns.

Why it matters — A fraud investigation notice signals potential legal or regulatory scrutiny that MYGN watchers would want to monitor.

MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

GlobeNewsWire · 6 Aug 2026negative

Law firm Kirby McInerney LLP announced it is investigating potential claims against Myriad Genetics. The investigation concerns whether the company and/or senior management may have violated federal securities laws or engaged in other unlawful business practices.

Why it matters — An active securities-fraud investigation into the company and its senior management signals potential legal and regulatory exposure for Myriad Genetics.

MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)

Business Wire · 5 Aug 2026negative

Levi & Korsinsky has notified investors of an investigation into Myriad Genetics after the company suspended its full-year 2026 adjusted EBITDA guidance, following an earlier reaffirmation on May 5, 2026 that included an adjusted EBITDA range of $37 million to $49 million and adjusted gross margin of 68% to 69%. The firm reports that shares dropped roughly three months later and encourages affected investors to submit their loss information or contact Joseph E. Levi.

Why it matters — A Myriad Genetics watcher would want to know about this because the suspended guidance, subsequent share decline, and announced investor investigation could signal legal or regulatory scrutiny tied to the company's financial communications.

FAQ

Frequently asked questions about MYGN stock

What is the MYGN stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Myriad Genetics, Inc. have a median 12-month price target of $3.6, with estimates ranging from $2.5 to $5.45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MYGN stock a buy right now?

Of the 9 analysts covering Myriad Genetics, Inc., 2 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Myriad Genetics, Inc. 52 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MYGN?

As at 22 Aug 2026, Myriad Genetics, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).

Will MYGN stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +18.4% from the last close, and Ticker Nerd's factor model ranks Myriad Genetics, Inc. 52 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MYGN stock forecast for 2030?

No analyst covering Myriad Genetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MYGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $5.45 over the next 12 months.

How has MYGN stock performed over the past year?

Myriad Genetics, Inc. returned -49.5% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Myriad Genetics, Inc. do?

Myriad Genetics Inc. is a biotechnology company specializing in the development and commercialization of genetic tests that assess risk for cancer and other hereditary conditions.

What is the latest news on MYGN?

The most recent item we track (Business Wire, 14 Aug 2026): "MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations". A law firm, Kirby McInerney LLP, has announced an investigation into Myriad Genetics and its senior management regarding potential violations of federal securities laws. The investigation follows the company's July 30, 2026 report of an 11% year-over-year decline in second-quarter revenue.

Company

About Myriad Genetics, Inc.

Myriad Genetics Inc. is a biotechnology company specializing in the development and commercialization of genetic tests that assess risk for cancer and other hereditary conditions. The company is renowned for its pioneering efforts in molecular diagnostics, offering tests that help individuals and healthcare providers make informed decisions about disease prevention and treatment. Myriad Genetics plays a critical role in the healthcare and medical research sectors by advancing personalized medicine and facilitating the understanding of genetic contributions to disease. Their testing portfolio includes products that identify genetic markers, providing insights into the likelihood of developing various cancers, such as breast and ovarian cancer, among other conditions. Myriad’s work supports oncologists, genetic counselors, and researchers by delivering highly reliable genetic insights crucial for patient care planning. Headquartered in Salt Lake City, Utah, Myriad Genetics continues to be at the forefront of genetic testing—driving innovation that enhances predictive medicine and impacts clinical decision-making.

CEO Mr. Samraat S. Raha · 2,700 employees · United States · https://www.myriad.com